🇮🇪Ireland
16°C Partly Cloudy · Dublin
Live Updates
--:--:-- IST
Writer Login
Latest
Priya Life Science Clinical trial register
TrackersDrugsComparisonsAPI
Trackers› Clinical trials› London
Clinical trial register · United Kingdom · industry-sponsored

Clinical Trials in London

Every industry-sponsored study on the ClinicalTrials.gov registry that lists a UK site and is open, about to open, active-but-closed, or enrolling by invitation. This deliberately excludes academic and other non-industry sponsors — the full UK registry across all sponsors is far larger. UK studies may also be registered separately on ISRCTN.

Download CSV
Source: ClinicalTrials.gov. Complete coverage of the industry-sponsored slice — all 2852 matching records are in this view (non-industry sponsors are out of scope by design, not truncated). Synced 17 Sep 2026, 08:23 UTC
2852
Studies in scope
industry-sponsored, all four open statuses
1378
Recruiting now
open to new participants
540
Lead sponsors
across recruiting studies
Top sites
London 2010 Manchester 675 Birmingham 472 Glasgow 439 Cambridge 416
Narrow the registerReset
Recruitment status
Phase
Lead sponsor
AstraZeneca136 Merck Sharp & Dohme LLC99 Hoffmann-La Roche80 Janssen Research & Development, LLC73 Novartis Pharmaceuticals72
Site city
London2010 Manchester675 Birmingham472 Glasgow439 Cambridge416
All 426 cities
Target enrolment
to
2010 of 2852 studies
Download
Status
Study
Lead sponsor
Phase
Enrol
UK sites
Start
By invitation
An Open-Label Extension Study to Evaluate the Long-term Safety and Efficacy of BMN 351 in Participants With Duchenne Muscular Dystrophy
NCT07573631Duchenne Muscular Dystrophy (DMD)
BioMarin Pharmaceutical
Phase 2
18
London
2026-04-20
Recruiting
OLE Study With Filgotinib in JIA
NCT07553182Juvenile Idiopathic Arthritis (JIA)
Alfasigma S.p.A.
Phase 3
80
London
2026-04-20
Recruiting
A Study to Test Whether Different Doses of BI 3000202 Help People With Systemic Lupus Erythematosus (SLE)
NCT07409181Systemic Lupus Erythematosus
Boehringer Ingelheim
Phase 2
405
Basingstoke, Belfast, Cambridge, Doncaster, London
2026-04-20
Recruiting
A Study of LY4584180 in Adult Participants With Previously Treated Blood Cancers
NCT07226843Lymphoma, Non-Hodgkin's, Lymphoma, Diffuse Large B-Cell, Follicular Lymphoma
Eli Lilly and Company
Phase 1
460
London, Nottingham, Plymouth, Southampton
2026-04-17
Recruiting
EncompaSSc: Evaluation of MTX-474 in Participants With Diffuse Cutaneous Systemic Sclerosis (dcSSc)
NCT07287670Diffuse Cutaneous Systemic Sclerosis
Mediar Therapeutics
Phase 2
85
Coventry, Liverpool, London, Westcliff-on-Sea
2026-04-16
Recruiting
A Study of LY4005130 in Adult Participants With Severe Alopecia Areata (Hair Loss)
NCT07533006Alopecia Areata
Eli Lilly and Company
Phase 2
60
London, Salford
2026-04-14
Recruiting
KHENERFIN Study: A Trial to Evaluate the Efficacy and Safety of Sonlicromanol in Primary Mitochondrial Diseases
NCT06451757Mitochondrial Diseases, Maternally Inherited Diabetes and Deafness (MIDD), Mitochondrial Encephalomyopathy, Lactic Acidosis and Stroke-like Episodes (MELAS), Mitochondrial DNA tRNALeu(UUR) m.3243A<G Mutation
Khondrion BV
Phase 3
220
London
2026-04-14
Recruiting
Controlling Hyperactive Immunity With Long-lived Lymphocytes
NCT07473154Diffuse Cutaneous Systemic Sclerosis, Rheumatoid Arthritis (RA), Systemic Sclerosis (SSc), Autoimmune Rheumatologic Disease
Quell Therapeutics Limited
Phase 1/2
16
Birmingham, Leeds, London, Manchester, Newcastle, Oxford
2026-04-10
Recruiting
A Study to Evaluate Chemotherapy With or Without INCB161734 in Previously Untreated, KRAS G12D-Mutated Metastatic Pancreatic Ductal Adenocarcinoma
NCT07522073Solid Tumors
Incyte Corporation
Phase 3
588
Dundee, Guildford, Headington, Leeds, London, Manchester, Northwood, Norwich
2026-04-09
Recruiting
A Gaucher Disease Gene Therapy Trial With FLT201
NCT07223944Gaucher Disease Type 1
Spur Therapeutics
Phase 3
45
Birmingham, Salford, London, Cambridge
2026-04-07
Recruiting
A Phase II Study Evaluating the Efficacy and Safety of Inavolisib Plus Ribociclib Plus Fulvestrant Versus Placebo Plus Ribociclib Plus Fulvestrant in Participants With Advanced Breast Cancer
NCT07405801Breast Cancer
Hoffmann-La Roche
Phase 2
80
Leicester, London, Manchester
2026-04-07
Recruiting
Phase 3 Extension Study of ADX-324 in Participants With Hereditary Angioedema (HAE)
NCT07428499Hereditary Angioedema (HAE), Hereditary Angioedema - Type 1, Hereditary Angioedema - Type 2, HAE
ADARx Pharmaceuticals, Inc.
Phase 3
90
Cambridge, Cardiff, London, Southampton
2026-04-02
Recruiting
A Study of YL201 in Combination With Other Anti-Cancer Therapies in Patients With Advanced Solid Tumors
NCT07407933Thoracic Neoplasms, Lung Diseases, Small Cell Lung Carcinoma
MediLink Therapeutics (Suzhou) Co., Ltd.
Phase 1/2
118
London
2026-03-31
Recruiting
PS-002 for the Treatment of IgA Nephropathy in Adults
NCT07182227Immunoglobulin A (IgA) Nephropathy
Purespring Therapeutics Limited
Phase 1/2
32
Manchester, Leicester, Nottingham, Bristol, Cardiff, Edinburgh, London
2026-03-30
Recruiting
A Study to Assess the Effect of Surovatamig in Adult Participants With Antibody-mediated Kidney Disease
NCT07571746Primary Membranous Nephropathy
AstraZeneca
Phase 2
43
London, Manchester
2026-03-28
Recruiting
A Clinical Trial of EYE201/MK-8748 in People With Macular Degeneration (MK-8748-002)
NCT07440225Macular Degeneration, Age-Related Macular Degeneration, Choroidal Neovascularization, Wet Macular Degeneration
EyeBiotech Ltd.
Phase 2/3
960
Leicester, London
2026-03-27
Recruiting
Safety, Tolerability, Pharmacokinetic, and Pharmacodynamic Study of ALXN2230 in Healthy Participants
NCT07352423Healthy Adult Participants
Alexion Pharmaceuticals, Inc.
Phase 1
48
London
2026-03-26
Recruiting
A Study to Evaluate the Safety, Tolerability, and Efficacy of Pumitamig Alone or in Combination With Other Agents in Participants With Advanced Renal Cell Carcinoma (RCC) (ROSETTA RCC-208)
NCT07293351Advanced Renal Cell Carcinoma (RCC)
Bristol-Myers Squibb
Phase 1/2
474
London, Preston, Cambridge, Cardiff, Edinburgh, Manchester, Sulton, Surrey
2026-03-26
Recruiting
A Study to Evaluate Safety and Efficacy of KarXT + KarX-EC as a Treatment for Psychosis Associated With Alzheimer's Disease (ADEPT-5)
NCT06947941Alzheimer Disease, Psychosis
Bristol-Myers Squibb
Phase 3
325
Exeter, London, Oxford, Chertsey, Sheffield, Crowborough, Motherwell
2026-03-25
Recruiting
A Long-Term Observational Study of Patients With Fucosidosis
NCT07615400Fucosidosis
JCR Pharmaceuticals Co., Ltd.
Observational
57
Belfast, Birmingham, London, Manchester, Salford
2026-03-25
Recruiting
Transition to KPL-387 Monotherapy Dosing & Administration Study
NCT07288216Recurrent Pericarditis, Heart Diseases, Pericarditis
Kiniksa Pharmaceuticals International, plc
Phase 2
80
London
2026-03-25
Recruiting
A Study to Investigate the Efficacy, Safety and Tolerability of Votoplam in Participants With Huntington's Disease
NCT07326709Huntington Disease
Novartis Pharmaceuticals
Phase 3
770
Exeter, Aberdeen, Cambridge, Cardiff, Glasgow, London, Oxford, Southampton
2026-03-24
Recruiting
Extension Study for Participants in Studies That Include Belzutifan (MK-6482-043/LITESPARK-043)
NCT07405164Von Hippel-Lindau Disease, Malignant Neoplasms
Merck Sharp & Dohme LLC
Phase 3
450
Glasgow, London, Manchester
2026-03-23
Recruiting
PODOMOUNT-Basket, a Study to Test Whether BI 764198 Helps Adults and Adolescents With Different Types of Kidney Disease
NCT07355296Proteinuric Kidney Diseases
Boehringer Ingelheim
Phase 2
132
Bradford, London, Salford
2026-03-23
Recruiting
A Phase 2/3 Study of Brepocitinib in Adults With Lichen Planopilaris
NCT07532603Lichen Planopilaris
Priovant Therapeutics, Inc.
Phase 2/3
342
Salford, Glasgow, Brighton, London, Wrexham
2026-03-19
Rows per page Showing 101–125 of 2010
Previous 3 4 5 6 7 Next
Cite this view

Priya Life Science (2026). Clinical trial register: industry-sponsored studies with a UK investigative site, filtered. Derived from ClinicalTrials.gov. Retrieved 19 September 2026. https://priyalifescience.com/clinical-trials-uk/city/london

Query this register directly
GET /api/trials?country=uk&status=recruiting&format=json Try it now →
Listing here is informational and not medical advice; eligibility is determined by each study team. Compare pay for the teams running these studies in the UK Pharma Salary Guide, or see the Ireland, EU and USA registers.